Best practices for treatment of retinal vein occlusion

Current Opinion in Ophthalmology

Volumn 23, Issue 3, 2012, Pages 175-181

  Hahn, Paul ^a   Fekrat, Sharon ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti VEGF; corticosteroids; intravitreal; macular edema; retinal vein occlusion

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL PRACTICE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VISUAL ACUITY; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; RETINAL VEIN OCCLUSION; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859697838     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283524148     Document Type: Review

References (68)

1. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011; 56:281-299.
2. Fekrat S, Shea AM, Hammill BG, et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin 2010; 26:223-230.
3. Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003; 121:1297-1302. (Pubitemid 37128408)
4. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98:271-282.
5. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion StudyGroup Mreport. Ophthalmology 1995; 102:1425-1433.
6. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986; 104:34-41.
7. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102:1434-1444.
8. Bressler NM, Schachat AP. Management of macular edema from retinal vein occlusions: you can never have too many choices. Ophthalmology 2010; 117:1061-1063.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487. (Pubitemid 24356306)
10. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009; 50:1025-1032.
11. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 2008; 22:42-48.
12. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27:141-149.
13. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144:864-871. (Pubitemid 350122344)
14. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007; 143:601-606.
15. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007; 245:1429-1436. (Pubitemid 47423323)
16. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008; 92:518-522. (Pubitemid 351497981)
17. Decroos FC, Ehlers JP, Stinnett S, Fekrat S. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Curr Eye Res 2011; 36:1164-1170.
18. Algvere PV, Epstein D, von Wendt G, et al. Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 2011; 21:789-795.
19. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011; 27:615-621.
20. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina 2011; 31:1856-1862.
21. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1102-1112; e1. The 6-month results of the phase III BRAVO trial prompted FDA-approval in 2010 of Lucentis for BRVO-associated macular edema.
22. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117:1124-1133; e1. The 6-month results of the phase III CRUISE trial prompted FDA-approval in 2010 of Lucentis for CRVO-associated macular edema.
23. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118:1594-1602. The 12-month results of the phase III BRAVO trial demonstrated sustained benefits with Lucentis for BRVO-associated macular edema.
24. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118:2041-2049. The 12-month results of the phase III CRUISE trial demonstrated sustained benefits with Lucentis for CRVO-associated macular edema.
25. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005; 25:851-855. (Pubitemid 41456575)
26. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136:419-425. (Pubitemid 37101237)
27. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye (Lond) 2005; 19:65-71. (Pubitemid 40192642)
28. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127:1115-1128.
29. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127:1101-1114.
30. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117:1134-1146; e3. The 6-month results of the phase III Ozurdex trial prompted FDA-approval in 2009 for RVO-associated macular edema.
31. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118:2453-2460. The 12-month results of the phase III Ozurdex trial demonstrated sustained benefits for RVO-associated macular edema. Side effects included cataract formation, not observed during the 6-month trial, and elevated IOP.
32. DeCroos FC, Shuler RK Jr, Stinnett S, Fekrat S. Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147:627-633; e1.
33. Park DH, Kim IT. Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion. Retina 2010; 30:117-124.
34. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142:1054-1056. (Pubitemid 44853889)
35. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136:1136-1150. (Pubitemid 37485782)
36. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131:61-77. (Pubitemid 32037010)
37. Cheung N, Klein R, Wang JJ, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49:4297-4302.
38. Di Capua M, Coppola A, Albisinni R, et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2010; 30:16-22.
39. O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126:692-699. (Pubitemid 351679566)
40. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240:180-196. (Pubitemid 36097054)
41. Mruthyunjaya P, Wirostko WJ, Chandrashekhar R, et al. Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. Retina 2006; 26:285-291. (Pubitemid 44318181)
42. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc 1996; 94:471-504. (Pubitemid 26406044)
43. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001; 108:2249-2257. (Pubitemid 33096938)
44. Ghazi NG, Noureddine B, Haddad RS, et al. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina 2003; 23:780-784. (Pubitemid 38040577)
45. Feltgen N, Junker B, Agostini H, Hansen LL. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology 2007; 114:716-723.
46. Hattenbach LO, Friedrich Arndt C, Lerche R, et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009; 29:932-940.
47. Fekrat S, de Juan E Jr. Chorioretinal venous anastomosis for central retinal vein occlusion: transvitreal venipuncture. Ophthalmic Surg Lasers 1999; 30:52-55. (Pubitemid 29042506)
48. Peyman GA, Kishore K, Conway MD. Surgical chorioretinal venous anastomosis for ischemic central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30:605-614. (Pubitemid 29450733)
49. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995; 113:456-462.
50. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 1998; 116:43-52. (Pubitemid 28098893)
51. McAllister IL, Gillies ME, Smithies LA, et al. The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology 2010; 117:954-965.
52. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999; 19:1-5. (Pubitemid 30387533)
53. Mason J 3rd, Feist R, White M Jr, et al. Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology 2004; 111:540-545. (Pubitemid 38293113)
54. Hwang JC, Gelman SK, Fine HF, et al. Combined arteriovenous sheathotomy and intraoperative intravitreal triamcinolone acetonide for branch retinal vein occlusion. Br J Ophthalmol 2010; 94:1483-1489.
55. Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001; 21:408-415. (Pubitemid 32971349)
56. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006; 26:297-305. (Pubitemid 44318183)
57. Arevalo JF, Garcia RA, Wu L, et al. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 2008; 28:1044-1052.
58. Hasselbach HC, Ruefer F, Feltgen N, et al. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefes Arch Clin Exp Ophthalmol 2007; 245:1145-1156. (Pubitemid 47034338)
59. Crama N, Gualino V, Restori M, Charteris DG. Central retinal vessel blood flow after surgical treatment for central retinal vein occlusion. Retina 2010; 30:1692-1697.
60. Skevas C, Wagenfeld L, Feucht M, et al. Radial optic neurotomy in central retinal vein occlusion does not influence ocular hemodynamics. Ophthalmologica 2011; 225:41-46.
61. Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol 2011; 5:705-713.
62. Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion: consensus document. Ophthalmologica 2011; 226:4-28. Collaborative European consensus document on management of RVO based on published results up to December 2010.
63. Ding X, Li J, Hu X, et al. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 2011; 31:838-845.
64. Ehlers JP, Fekrat S. Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. Can J Ophthalmol 2011; 46:88-89.
65. Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, et al. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci 2011; 52:3334-3337.
66. Salinas-Alaman A, Zarranz-Ventura J, Caire Gonzalez-Jauregui JM, et al. Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2011; 21:434-439.
67. Ogino K, Tsujikawa A, Murakami T, et al. Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. Clin Ophthalmol 2011; 5:1031-1036.
68. Shah NJ, Shah UN. Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study. Eye (Lond) 2011; 25:239-244.